Ibtrozi (Taletrectinib)

Taletrectinib is a medicine used to treat a type of lung cancer that has a change in a gene called ROS1. It is taken as a capsule by mouth. It works by blocking the ROS1 signal that drives the cancer cells to grow.

Brand names:Ibtrozi
Medication

What people taking Ibtrozi (Taletrectinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Ibtrozi (Taletrectinib) for Non-Small Cell Lung Cancer?

NameHow it went

About Ibtrozi (Taletrectinib)

What It's For

Taletrectinib, sold under the brand name Ibtrozi, is a targeted cancer medicine for adults with ROS1-positive non-small cell lung cancer (NSCLC) that is locally advanced or metastatic, meaning it has spread to other parts of the body. Non-small cell lung cancer is the more common of the two main types of lung cancer. In some of these cancers, part of a gene called ROS1 has broken off and joined with another gene, and that fused gene drives the cancer's growth. Doctors find this change by testing a sample of the tumor, and taletrectinib is meant only for people whose tumor carries it. It can be the first ROS1-targeted medicine a person takes, or it can be used after an earlier one, such as crizotinib (Xalkori) or entrectinib (Rozlytrek), has stopped controlling the cancer. Having had chemotherapy before does not rule it out.

How It Works

The ROS1 gene carries instructions for a tyrosine kinase, a protein that works like a switch telling cells when to grow. When ROS1 is fused with another gene, that switch is stuck on, and the fused protein keeps sending growth signals that let cancer cells multiply without the usual limits. Taletrectinib is a kinase inhibitor: it blocks the overactive ROS1 protein, which can shrink tumors or stop them from growing. Over time, cancers treated with an earlier ROS1 medicine can develop new changes in ROS1 that let them escape it. Taletrectinib also blocks some of these resistance changes, which is part of why it can still work after another ROS1 medicine has failed. Lung cancer can spread to the brain, and in the studies tumors in the brain also shrank in about two thirds of the people who had measurable brain tumors.

Dosage & Administration

Taletrectinib comes as 200 mg capsules taken by mouth. The usual dose is 600 mg (three capsules) once a day, at about the same time each day, on an empty stomach: nothing to eat for at least 2 hours before and 2 hours after each dose. The timing matters for safety, not just absorption, because taking it with food can increase its effect on the heart's rhythm. Grapefruit and grapefruit juice should be avoided throughout treatment. Swallow the capsules whole, without opening, chewing or crushing them. If a dose is missed, or if you vomit after taking it, skip it and take the next dose at the usual time the following day rather than doubling up. If side effects become a problem, the care team may pause treatment or lower the dose to 400 mg or 200 mg a day. In the main studies, about 3 in 10 people needed a lower dose at some point.

Side Effects

Digestive side effects are the most common. In the main studies, about two thirds of people had diarrhea and nearly half had nausea or vomiting. Constipation, dizziness, rash, tiredness, changes in taste, lower appetite, cough, and tingling or numbness in the hands and feet were also common. Most of these were not severe, but tell the care team if any are severe or do not go away. Taletrectinib also makes skin burn more easily, so limit time in the sun and use broad-spectrum sunscreen and protective clothing during treatment and for at least 5 days after the last dose. Blood tests often show changes that cause no symptoms. Raised liver enzymes appear in most people, often within the first few weeks, and occasionally become serious liver injury, which has rarely been fatal. Contact the care team right away for yellowing of the skin or eyes, dark urine, pale stools, or unusual stomach pain with loss of appetite. A small number of people develop pneumonitis, an inflammation of the lungs that can be life-threatening. New or worsening shortness of breath, cough or fever needs a call to the care team right away. So does feeling faint or lightheaded or a racing heartbeat, which can signal a heart rhythm problem. Actually fainting, or severe trouble breathing at rest, needs emergency care. Taletrectinib can also raise the risk of fractures, so report bone pain or a change in how you move. Unexplained muscle pain or weakness, and swollen, red or painful joints from high uric acid (the cause of gout), should also be reported.

Interactions & Warnings

Taletrectinib is broken down by a liver enzyme called CYP3A, so medicines that slow or speed that enzyme change how much of the drug is in the body. Strong or moderate CYP3A blockers, which include antifungal medicines such as itraconazole and fluconazole, the antibiotic erythromycin and the blood pressure and heart medicine verapamil, raise its level and make side effects, including heart rhythm effects, more likely. Medicines that speed CYP3A up, such as the tuberculosis antibiotic rifampin, the HIV medicine efavirenz and the herbal supplement St. John's wort, lower its level and can make it less effective. Both kinds of combination are generally avoided. Acid-reducing medicines also matter: proton pump inhibitors such as omeprazole and H2 blockers such as famotidine reduce absorption and should be avoided, and an antacid such as calcium carbonate should be taken at least 2 hours before or after a dose. The care team and pharmacist need a full list of prescriptions, over-the-counter products and supplements before any change. Taletrectinib can lengthen the QT interval, a part of the heartbeat measured on an electrocardiogram (ECG). A markedly long QT interval raises the risk of a dangerous irregular heartbeat. For that reason, other medicines that also lengthen the QT interval, such as some heart rhythm medicines, are usually avoided, and people with long QT syndrome, a slow heart rhythm or heart failure need closer monitoring. Mention any liver disease, lung problems other than the cancer, or gout before starting as well. Taletrectinib can harm a developing baby. A pregnancy test is done before starting, and women who could become pregnant, as well as men with partners who could become pregnant, should use effective birth control during treatment and for 3 weeks after the last dose. Breastfeeding should stop during treatment and for 3 weeks afterward. Animal studies suggest it may reduce fertility in both men and women, which is worth discussing beforehand if future children matter.

What to Expect

Before the first dose, the care team checks liver blood tests, uric acid, electrolytes (minerals in the blood) and an ECG. Liver tests are repeated every 2 weeks for the first 2 months and then about monthly, with ECGs and other labs repeated during treatment. Testing is most frequent early on because liver enzyme changes typically show up in the first weeks. Progress is tracked with regular scans. In the studies, about 9 in 10 people who had not taken a ROS1 medicine before saw their tumors shrink, and responses were often long-lasting: about 7 in 10 lasted at least a year, and in the larger study half lasted longer than about 4 years. Results were lower after an earlier ROS1 medicine, with roughly half to 6 in 10 responding and shorter responses, around a year at the median in one study. Individual results vary widely. These were studies without a comparison group, so they show how often and how long tumors shrank, not how taletrectinib compares with other ROS1 medicines on survival. Treatment usually continues until the cancer starts growing again or side effects become too hard to manage, and at that point the care team discusses next options.

Questions to Ask Your Doctor

  1. 1.How was the ROS1 change found in my tumor, and do we need any further testing now or if the cancer grows later?
  2. 2.Why is taletrectinib a good fit for me compared with other ROS1 medicines, and what would we try if it stops working?
  3. 3.Which of my current medicines, including acid reducers and supplements, need to change, and how should I fit the empty-stomach timing into my day?
  4. 4.What schedule of blood tests, ECGs and scans should I expect, and what results would lead you to pause or lower my dose?
  5. 5.Which symptoms should I call about right away, and how do I reach the team after hours?

Last reviewed • Oct 2026

Educational content, not medical advice.